rare diseases

reshuffle pipeline target reorganize shift change
Biotech

Recursion streamlines pipeline following merger with Exscientia

Evidently in the mood for spring cleaning, Recursion is clearing out part of its pipeline as it narrows its focus on oncology and rare diseases.
Fraiser Kansteiner May 5, 2025 11:00am
red tape delay stop error tie down stall

FDA misses PDUFA date for Stealth’s ultra-rare disease candidate

Apr 30, 2025 9:00am
brain money funding

Biohaven lands funding Oberland funding deal worth up to $600M

Apr 28, 2025 4:43pm
Business person contemplating how to navigate a maze made of money

Glycomine's $115M series C to fund genetic disorder ph. 2 plans

Apr 16, 2025 9:20am
Graphic image of a pen signing a signature while two strangelooking business people cheer

Spruce inks deal for BioMarin asset, plans 2026 approval filing

Apr 15, 2025 10:29am
An arrow incrementally going up stairs before pointing straight up Blue background

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

Mar 17, 2025 7:25am